Glenmark Pharmaceuticals Inc. USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials, which are expected to deliver the same therapeutic effect as the branded drug product Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc.

Acetylcysteine, a widely used therapeutic agent, is employed to treat acetaminophen overdose and as a mucolytic agent in managing respiratory conditions.

Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, remarked, “We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the U.S. market as we continue to drive growth for the hospital segment.”

More Glenmark News

In February, Glenmark launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution.